Terms ending in 2033
Every in-force patent on Aclarion, Inc.'s record whose computed term ends in 2033, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,345,421 | Magnetic Resonance Spectroscopy Pulse Sequence, Acquisition, and Processing System and Method In force · High confidence | Aclarion, Inc. | In force | High confidence | |
| US 10,045,711 | Magnetic Resonance Spectroscopy Pulse Sequence, Acquisition, and Processing System and Method In force · High confidence | Aclarion, Inc. | In force | High confidence | |
| US 10,646,135 | Magnetic Resonance Spectroscopy Pulse Sequence, Acquistion, and Processing System and Method In force · Low confidence | Aclarion, Inc. | In force | Low confidence | |
| US 11,179,057 | Magnetic Resonance Spectroscopy Pulse Sequence, Acquisition, and Processing System and Method In force · Medium confidence | Aclarion, Inc. | In force | Medium confidence | |
| US 11,633,124 | Magnetic Resonance Spectroscopy Pulse Sequence, Acquisition, and Processing System and Method In force · Medium confidence | Aclarion, Inc. | In force | Medium confidence | |
| US 12,097,020 | Magnetic Resonance Spectroscopy Pulse Sequence, Acquisition, and Processing System and Method In force · Medium confidence | Nocimed, LLC | In force | Medium confidence | |
| US 8,965,094 | Magnetic Resonance Spectroscopy Pulse Sequence, Acquisition, and Processing System and Method In force · High confidence | Aclarion, Inc. | In force | High confidence |
7 of 7 patents shown. Soonest term end first, then patent number.
6 of these are in force and held by Aclarion, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.